Stubborn Tuberculosis, a Red Alert for India

On World TB Day, a city paediatrician who was part of Medecins Sans Frontieres shares his view on how diagnosis & treatment can be improved Drug Resistance is a challenge that needs to be tackled and new drugs need to come up: there has been only 1 new drug in the past 50 years

Published: 24th March 2016 05:06 AM  |   Last Updated: 24th March 2016 05:06 AM   |  A+A-


CHENNAI: In a country where there were about 25 lakh cases of tuberculosis and 2.2 lakh deaths from the disease in 2014, India now faces a massive threat of drug resistance. “About 8-9 decades back, there were not many effective drugs for TB and patients would be put in sanitoria and be given good nutrition. Now, we are at a crossroads. Extreme drug resistance could pull us down into the same situation again,” warns Aravind Swaminathan, a pediatrician who has worked extensively with patients in South Sudan and Tajikistan, as part of a Medecins Sans Frontieres (MSF, Doctors Without Borders) team. In India, according to WHO’s global tuberculosis report 2015, 2.2% of new TB cases and 15% of re-treatment cases have Multi Drug Resistance (MDR).

Diagnostic Challenge

Stubborn.jpgDiagnosing TB, especially in children, remains a challenge, says Dr Aravind. The most common form of the disease is chest TB. “Children do not have enough pressure in the chest to bring out sputum, a fluid from the respiratory tract, for the most common method of testing — sputum microscopy (viewing the sputum under a microscope and looking for TB bacteria). So, sample collection methods need to improved,” he says. For instance, secretions from their stomach early in the morning can be used. There is also a newer test called Genexpert, which looks for the genes of the bacteria. It also gives information like sensitivity of the bacteria to a first line drug. Another plus with this method is that the results can be obtained in 3-4 hours,” he explains. This is a boon for diagnosis. However, has not been subsidised on a large scale yet. The equipment costs about $17,000. We need to work on making it available to those who need it,” he says.

Treatment & Resistance

Stubbo.JPGEnsuring a continuous supply of drugs is key for treating TB. “Compliance is the crux of TB treatment. In fact, delaying the treatment is better than getting incomplete treatment,” says Dr Aravind. This is because if the drugs are stopped anytime during treatment, the bacillus develops resistance to the drug. At present, India practices a thrice-a-week treatment regimen. “It’s high time we move on to every day treatment. There needs to be more research to develop newer drugs – in the past 50 years, only one drug – bedaquiline – has been developed and even this isn’t authorised for use by the WHO for minors,” he explains.

Stigma Removal

“The image of TB in many communities is a thin man coughing blood and dying. People have to be made aware that this is not so,” says Dr Aravind. “Tuberculosis contributes to one of the biggest disease burdens and school students need to be made aware — of at least the basics. This will go a long way in removing the stigma,” he says, adding that patients who come to him with persistent cough often go on the backfoot. “The minute you ask them if they’ve heard of TB and if anyone in their family has TB, they immediately say no, nothing like that, it can’t be TB. People should understand that this is a respiratory disease that can affect anyone.”


Stay up to date on all the latest Chennai news with The New Indian Express App. Download now


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp